NO317178B1 - Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen - Google Patents

Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen Download PDF

Info

Publication number: NO317178B1
Authority: NO; Norway
Prior art keywords: norcisapride; pharmaceutically acceptable; use according; acceptable salt; per day
Prior art date: 1996-07-19

Application number

NO19983636A

Other languages

English (en)

Norwegian (no)

Other versions

NO983636L (no

NO983636D0 (no

Inventor

Thomas P Jerussi

John R Mccullough

Original Assignee

Sepracor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-19

Filing date

1998-08-07

Publication date

2004-09-06

1998-08-07 Application filed by Sepracor Inc filed Critical Sepracor Inc

1998-08-07 Publication of NO983636D0 publication Critical patent/NO983636D0/no

1998-10-19 Publication of NO983636L publication Critical patent/NO983636L/no

2004-09-06 Publication of NO317178B1 publication Critical patent/NO317178B1/no

Links

ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 title claims abstract description 89
239000003814 drug Substances 0.000 title claims abstract description 52
239000002552 dosage form Substances 0.000 title claims description 21
238000004519 manufacturing process Methods 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 title abstract description 50
239000008194 pharmaceutical composition Substances 0.000 title description 2
OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 claims abstract description 51
229940079593 drug Drugs 0.000 claims abstract description 33
238000011282 treatment Methods 0.000 claims abstract description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
210000003169 central nervous system Anatomy 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims description 31
201000010099 disease Diseases 0.000 claims description 21
230000003542 behavioural effect Effects 0.000 claims description 13
239000003937 drug carrier Substances 0.000 claims description 11
239000002775 capsule Substances 0.000 claims description 9
208000019022 Mood disease Diseases 0.000 claims description 7
230000003474 anti-emetic effect Effects 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
239000007905 soft elastic gelatin capsule Substances 0.000 claims description 4
208000017194 Affective disease Diseases 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 3
206010026749 Mania Diseases 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 3
208000019906 panic disease Diseases 0.000 claims description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
239000006194 liquid suspension Substances 0.000 claims 2
238000001802 infusion Methods 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
229940001470 psychoactive drug Drugs 0.000 claims 1
239000004089 psychotropic agent Substances 0.000 claims 1
230000037317 transdermal delivery Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 63
238000000034 method Methods 0.000 abstract description 19
230000002411 adverse Effects 0.000 abstract description 12
239000002111 antiemetic agent Substances 0.000 abstract description 5
229940125683 antiemetic agent Drugs 0.000 abstract description 4
230000003389 potentiating effect Effects 0.000 abstract description 4
206010013710 Drug interaction Diseases 0.000 abstract description 3
208000035475 disorder Diseases 0.000 abstract description 2
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 83
229960005132 cisapride Drugs 0.000 description 79
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 79
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 31
238000002360 preparation method Methods 0.000 description 23
238000012360 testing method Methods 0.000 description 20
206010047700 Vomiting Diseases 0.000 description 19
210000004027 cell Anatomy 0.000 description 17
229940124597 therapeutic agent Drugs 0.000 description 17
239000000203 mixture Substances 0.000 description 16
238000004458 analytical method Methods 0.000 description 15
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
239000003446 ligand Substances 0.000 description 13
239000007788 liquid Substances 0.000 description 12
229940076279 serotonin Drugs 0.000 description 12
239000000126 substance Substances 0.000 description 12
239000003826 tablet Substances 0.000 description 12
239000004480 active ingredient Substances 0.000 description 11
230000004044 response Effects 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
150000003936 benzamides Chemical class 0.000 description 10
206010010774 Constipation Diseases 0.000 description 9
230000009471 action Effects 0.000 description 9
239000008280 blood Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000000243 solution Substances 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
230000000968 intestinal effect Effects 0.000 description 8
230000004060 metabolic process Effects 0.000 description 8
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
230000008673 vomiting Effects 0.000 description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
206010021518 Impaired gastric emptying Diseases 0.000 description 7
241000282339 Mustela Species 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000027455 binding Effects 0.000 description 7
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
229960004316 cisplatin Drugs 0.000 description 7
201000006549 dyspepsia Diseases 0.000 description 7
208000001288 gastroparesis Diseases 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
239000007787 solid Substances 0.000 description 7
108091005482 5-HT4 receptors Proteins 0.000 description 6
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
206010052105 Gastrointestinal hypomotility Diseases 0.000 description 6
201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
206010054048 Postoperative ileus Diseases 0.000 description 6
239000000556 agonist Substances 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000011260 co-administration Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000007958 sleep Effects 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
206010012735 Diarrhoea Diseases 0.000 description 5
230000003187 abdominal effect Effects 0.000 description 5
239000002585 base Substances 0.000 description 5
230000002526 effect on cardiovascular system Effects 0.000 description 5
230000005176 gastrointestinal motility Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 5
210000003205 muscle Anatomy 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
210000002460 smooth muscle Anatomy 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 4
108091005479 5-HT2 receptors Proteins 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
241000282341 Mustela putorius furo Species 0.000 description 4
241000906446 Theraps Species 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
102000005936 beta-Galactosidase Human genes 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
230000003684 cardiac depression Effects 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
239000002895 emetic Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
229960004125 ketoconazole Drugs 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
230000035939 shock Effects 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000000969 carrier Substances 0.000 description 3
235000013339 cereals Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000001143 conditioned effect Effects 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
230000006870 function Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
239000002325 prokinetic agent Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
238000011699 spontaneously hypertensive rat Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000035488 systolic blood pressure Effects 0.000 description 3
238000012549 training Methods 0.000 description 3
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
108091005477 5-HT3 receptors Proteins 0.000 description 2
102000035037 5-HT3 receptors Human genes 0.000 description 2
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
208000000103 Anorexia Nervosa Diseases 0.000 description 2
206010003011 Appendicitis Diseases 0.000 description 2
229930003347 Atropine Natural products 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
206010048610 Cardiotoxicity Diseases 0.000 description 2
208000002881 Colic Diseases 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
201000003066 Diffuse Scleroderma Diseases 0.000 description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
208000002720 Malnutrition Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000008238 Muscle Spasticity Diseases 0.000 description 2
206010068871 Myotonic dystrophy Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
240000006394 Sorghum bicolor Species 0.000 description 2
235000011684 Sorghum saccharatum Nutrition 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
201000009594 Systemic Scleroderma Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
235000009430 Thespesia populnea Nutrition 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 2
229960002054 acenocoumarol Drugs 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
229960000396 atropine Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
231100000259 cardiotoxicity Toxicity 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
230000029087 digestion Effects 0.000 description 2
208000010643 digestive system disease Diseases 0.000 description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009509 drug development Methods 0.000 description 2
230000000095 emetic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
-1 fluoketin Chemical compound 0.000 description 2
208000020694 gallbladder disease Diseases 0.000 description 2
210000003736 gastrointestinal content Anatomy 0.000 description 2
230000007160 gastrointestinal dysfunction Effects 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000001071 malnutrition Effects 0.000 description 2
235000000824 malnutrition Nutrition 0.000 description 2
229960004715 morphine sulfate Drugs 0.000 description 2
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 2
230000004899 motility Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
208000015380 nutritional deficiency disease Diseases 0.000 description 2
230000036407 pain Effects 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
229960000620 ranitidine Drugs 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
208000018198 spasticity Diseases 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
229960000351 terfenadine Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241000581650 Ivesia Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000003994 anesthetic gas Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
238000007262 aromatic hydroxylation reaction Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960004754 astemizole Drugs 0.000 description 1
230000037424 autonomic function Effects 0.000 description 1
IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
231100000457 cardiotoxic Toxicity 0.000 description 1
230000001451 cardiotoxic effect Effects 0.000 description 1
229960004841 cefadroxil Drugs 0.000 description 1
NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
108091008690 chemoreceptors Proteins 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
229940105442 cisplatin injection Drugs 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000004600 colonic motility Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
238000013480 data collection Methods 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002322 enterochromaffin cell Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
239000012458 free base Substances 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960000443 hydrochloric acid Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940090044 injection Drugs 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229940045996 isethionic acid Drugs 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
210000001853 liver microsome Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
229960002422 lomefloxacin Drugs 0.000 description 1
ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
210000000111 lower esophageal sphincter Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
244000309715 mini pig Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
229940068938 morphine injection Drugs 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
210000003249 myenteric plexus Anatomy 0.000 description 1
ITNXJLXLFAFOHO-UHFFFAOYSA-N n-piperidin-1-ylbenzamide Chemical group C=1C=CC=CC=1C(=O)NN1CCCCC1 ITNXJLXLFAFOHO-UHFFFAOYSA-N 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
OMLDMGPCWMBPAN-UHFFFAOYSA-N norcisapride Chemical compound COC1CNCCC1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-UHFFFAOYSA-N 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
210000005037 parasympathetic nerve Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
230000037322 slow-wave sleep Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960004576 temafloxacin Drugs 0.000 description 1
238000010998 test method Methods 0.000 description 1
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
229950010357 tetrodotoxin Drugs 0.000 description 1
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000001515 vagal effect Effects 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19983636A 1996-07-19 1998-08-07 Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen NO317178B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/684,753 US5739151A (en)	1996-07-19	1996-07-19	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en)	1996-07-19	1997-07-02	Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (3)

Publication Number	Publication Date
NO983636D0 NO983636D0 (no)	1998-08-07
NO983636L NO983636L (no)	1998-10-19
NO317178B1 true NO317178B1 (no)	2004-09-06

Family

ID=24749413

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19983636A NO317178B1 (no)	1996-07-19	1998-08-07	Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen
NO20041166A NO20041166L (no)	1996-07-19	2004-03-19	Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20041166A NO20041166L (no)	1996-07-19	2004-03-19	Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament

Country Status (25)

Country	Link
US (3)	US5739151A (el)
EP (1)	EP0896539B1 (el)
JP (1)	JP3097697B2 (el)
KR (4)	KR100422492B1 (el)
CN (1)	CN1215992A (el)
AT (1)	ATE197762T1 (el)
AU (1)	AU3592097A (el)
BG (1)	BG63190B1 (el)
BR (1)	BR9708287A (el)
CA (1)	CA2245768C (el)
CZ (1)	CZ293478B6 (el)
DE (1)	DE69703617T2 (el)
DK (1)	DK0896539T3 (el)
ES (1)	ES2152687T3 (el)
GR (1)	GR3035460T3 (el)
HU (1)	HUP9904360A3 (el)
IL (1)	IL125703A0 (el)
IS (1)	IS4820A (el)
NO (2)	NO317178B1 (el)
NZ (1)	NZ331291A (el)
PL (1)	PL189610B1 (el)
PT (1)	PT896539E (el)
SK (1)	SK282673B6 (el)
TR (1)	TR199801816T2 (el)
WO (1)	WO1998003173A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5712293A (en) *	1995-06-07	1998-01-27	Sepracor, Inc.	Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) *	1996-07-19	2000-11-14	Sepracor Inc.	Methods for treating gastroesophageal reflux disease
WO1998016511A1 (en) *	1996-10-15	1998-04-23	Janssen Pharmaceutica N.V.	Synthesis of cisapride
JP3529102B2 (ja) *	1997-07-11	2004-05-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド
TR200103759T2 (tr) *	1998-06-15	2002-06-21	Sepracor Inc.	Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
PT1089733E (pt)	1998-06-15	2005-08-31	Sepracor Inc	Utilizacao de (+)-norcisaprida optixamente pura para tratamento da sindroma do colon irritavel
EP1468685A3 (en) *	1998-06-15	2004-12-15	Sepracor Inc.	Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) *	1998-06-15	2004-12-15	Sepracor Inc.	Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
KR100529659B1 (ko) *	1998-08-21	2005-11-21	노파르티스 아게	5-ｈｔ4 작동제 또는 길항제를 위한 신규한 경구 투여용제제
US6362202B1 (en) *	1999-03-02	2002-03-26	Sepracor Inc.	Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) *	1999-03-02	2002-03-05	Sepracor, Inc.	Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6803387B1 (en)	1999-03-19	2004-10-12	Abbott Gmbh & Co. Kg	Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) *	2001-12-21	2003-06-25	Novartis AG	Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) *	2003-04-23	2006-08-04	Centre Nat Rech Scient	Vecteur pour administration par voie orale
PT2194053E (pt) *	2004-01-07	2013-07-08	Armetheon Inc	Derivados de metoxipiperidina para utilização no tratamento de distúrbios gastrointestinais e do sistema nervoso central
US8138204B2 (en) *	2004-01-07	2012-03-20	Aryx Therapeutics, Inc.	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en)	2004-01-07	2013-09-03	Armetheon, Inc.	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170899A1 (en) *	2004-09-14	2009-07-02	Guy Debonnel	Stimulators of 5-HT4 receptors and uses thereof
WO2007028073A2 (en) *	2005-08-31	2007-03-08	Aryx Therapeutics, Inc.	Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) *	2006-06-23	2007-12-27	Aryx Therapeutics, Inc.	Piperidine derivatives for the treatment of gastrointestinal and cns disorders
US20120208892A1 (en)	2009-10-16	2012-08-16	Epiomed Therapeutics, Inc.	Emesis treatment
PL2678332T3 (pl) *	2011-02-25	2016-12-30		Pochodne diaminopirymidyny i sposoby ich wytwarzania

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5137896A (en) *	1981-10-01	1992-08-11	Janssen Pharmaceutica N.V.	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) *	1981-10-01	1990-10-09	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) *	1981-10-01	1991-10-15	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (en) *	1981-10-01	1985-03-12	Georges Van Daele	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114715A (en) *	1990-11-29	1992-05-19	Sepracor Inc.	Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) *	1990-11-29	1992-05-19	Sepracor, Inc.	Methods of use and compositions of (r)-isoflurane and (r)-desflurane
EP0649307A4 (en) *	1992-07-07	1996-06-26	Sepracor Inc	METHOD FOR USING (-) - CISAPRIDE FOR TREATING GASTIC EYE ELEMENTS AND OTHER DISEASES.
EP1170010A3 (en) *	1992-07-07	2004-05-19	Sepracor Inc.	Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1995001803A1 (en) *	1993-07-06	1995-01-19	Merck & Co., Inc.	H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) *	1995-06-07	1998-01-27	Sepracor, Inc.	Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

1996
- 1996-07-19 US US08/684,753 patent/US5739151A/en not_active Expired - Fee Related
1997
- 1997-07-02 CZ CZ19982508A patent/CZ293478B6/cs not_active IP Right Cessation
- 1997-07-02 HU HU9904360A patent/HUP9904360A3/hu unknown
- 1997-07-02 WO PCT/US1997/011629 patent/WO1998003173A1/en active IP Right Grant
- 1997-07-02 ES ES97932467T patent/ES2152687T3/es not_active Expired - Lifetime
- 1997-07-02 SK SK1239-98A patent/SK282673B6/sk unknown
- 1997-07-02 DE DE69703617T patent/DE69703617T2/de not_active Expired - Fee Related
- 1997-07-02 KR KR10-2001-7011625A patent/KR100422492B1/ko not_active IP Right Cessation
- 1997-07-02 KR KR10-2003-7013889A patent/KR100533237B1/ko not_active IP Right Cessation
- 1997-07-02 DK DK97932467T patent/DK0896539T3/da active
- 1997-07-02 KR KR10-2001-7011626A patent/KR100399808B1/ko not_active IP Right Cessation
- 1997-07-02 AT AT97932467T patent/ATE197762T1/de not_active IP Right Cessation
- 1997-07-02 PT PT97932467T patent/PT896539E/pt unknown
- 1997-07-02 CA CA002245768A patent/CA2245768C/en not_active Expired - Fee Related
- 1997-07-02 JP JP10506954A patent/JP3097697B2/ja not_active Expired - Fee Related
- 1997-07-02 NZ NZ331291A patent/NZ331291A/en unknown
- 1997-07-02 BR BR9708287-2A patent/BR9708287A/pt not_active Application Discontinuation
- 1997-07-02 AU AU35920/97A patent/AU3592097A/en not_active Abandoned
- 1997-07-02 KR KR1019980706152A patent/KR100328731B1/ko not_active IP Right Cessation
- 1997-07-02 IL IL12570397A patent/IL125703A0/xx unknown
- 1997-07-02 TR TR1998/01816T patent/TR199801816T2/xx unknown
- 1997-07-02 CN CN97192157A patent/CN1215992A/zh active Pending
- 1997-07-02 EP EP97932467A patent/EP0896539B1/en not_active Expired - Lifetime
- 1997-07-02 PL PL97335254A patent/PL189610B1/pl not_active IP Right Cessation
- 1997-08-05 US US08/905,941 patent/US5877188A/en not_active Expired - Fee Related
1998
- 1998-07-13 US US09/114,319 patent/US6114356A/en not_active Expired - Fee Related
- 1998-08-07 NO NO19983636A patent/NO317178B1/no unknown
- 1998-08-10 IS IS4820A patent/IS4820A/is unknown
- 1998-09-09 BG BG102757A patent/BG63190B1/bg unknown
2001
- 2001-02-22 GR GR20010400294T patent/GR3035460T3/el not_active IP Right Cessation
2004
- 2004-03-19 NO NO20041166A patent/NO20041166L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2245768A1 (en)	1998-01-29
KR20040007505A (ko)	2004-01-24
NO983636L (no)	1998-10-19
BR9708287A (pt)	2000-01-18
DK0896539T3 (da)	2001-02-19
DE69703617D1 (de)	2001-01-04
EP0896539A1 (en)	1999-02-17
KR20000064524A (ko)	2000-11-06
US5739151A (en)	1998-04-14
CZ293478B6 (cs)	2004-05-12
WO1998003173A1 (en)	1998-01-29
ES2152687T3 (es)	2001-02-01
US6114356A (en)	2000-09-05
HUP9904360A3 (en)	2001-07-30
GR3035460T3 (en)	2001-05-31
TR199801816T2 (xx)	2000-10-23
EP0896539B1 (en)	2000-11-29
US5877188A (en)	1999-03-02
JP3097697B2 (ja)	2000-10-10
IS4820A (is)	1998-08-10
IL125703A0 (en)	1999-04-11
ATE197762T1 (de)	2000-12-15
KR100399808B1 (ko)	2003-09-29
CA2245768C (en)	2003-09-30
PL189610B1 (pl)	2005-08-31
BG102757A (en)	1999-08-31
NO983636D0 (no)	1998-08-07
CN1215992A (zh)	1999-05-05
PT896539E (pt)	2001-05-31
DE69703617T2 (de)	2001-04-12
HUP9904360A2 (hu)	2000-05-28
PL335254A1 (en)	2000-04-10
JPH11510828A (ja)	1999-09-21
KR100422492B1 (ko)	2004-03-11
BG63190B1 (bg)	2001-06-29
AU3592097A (en)	1998-02-10
SK123998A3 (en)	1999-03-12
NO20041166L (no)	2004-03-19
SK282673B6 (sk)	2002-11-06
KR100533237B1 (ko)	2005-12-05
NZ331291A (en)	2000-06-23
KR100328731B1 (ko)	2002-10-19
CZ250898A3 (cs)	1999-04-14

Publication	Publication Date	Title
NO317178B1 (no)	2004-09-06	Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen
EP1462104B1 (en)	2007-01-24	Optically pure (-) norcisapride for treating digestive tract disorders
US6147093A (en)	2000-11-14	Methods for treating gastroesophageal reflux disease
AU780107B2 (en)	2005-03-03	Methods for treating emesis and central nervous system disorders using optically pure () norcisapride
MXPA01000919A (en)	2002-03-26	Methods and compositions for treating gastro-esophageal reflux disease
AU2004200165A1 (en)	2004-02-12	Methods and compositions for treating gastro-esophageal reflux disease